The invention provides quinazoline-7-ether derivatives, particularly 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives that are inhibitors of the receptor protein tyrosine kinases (RTK). The compounds are useful in the treatment of diseases and disorders where RTK activity is implicated such as a hyperproliferative diseases (e.g., cancer). Also provided are methods of preparation of the quinazoline derivatives and methods of use as therapeutic agents alone or in a drug combination.
这项发明提供了
喹唑啉-7-醚衍
生物,特别是对受体
蛋白酪氨酸激酶(RTK)具有抑制作用的4-
苯胺基-6-
丁烯酰胺基-
喹唑啉-7-醚衍
生物。这些化合物在治疗RTK活性参与的疾病和紊乱方面具有用途,如高增殖性疾病(例如癌症)。还提供了制备
喹唑啉衍
生物的方法以及作为治疗剂单独使用或与药物组合使用的方法。